Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  CSL Limited    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

CSL : Urban League, CSL Behring Partner to Address Community Needs including Public Health, Workforce Diversity, Leadership Development

11/17/2020 | 08:52am EST

Global biotherapeutics leader CSL Behring today announced a community partnership with six Urban League affiliates across the U.S., starting with the Urban League of Philadelphia.

The partnership includes CSL Behring providing support to address the most pressing needs of the communities where the six Urban League affiliates serve and where the company has a strong community presence.

Areas of focus will include strengthening Public Health, Leadership Development, Workforce Diversity and Job Creation and Training. The partnership will also work toward the goal of improving understanding and awareness about plasma donation in coordination with CSL Plasma centers in each of the affiliates' communities.

'We are honored to work with the Urban League of Philadelphia and the other National Urban League's affiliates throughout the U.S., with their rich history of serving communities and advancing economic empowerment, equality, and social justice,' said Paul Perreault, CEO and Managing Director of CSL Limited (parent company of CSL Behring.) 'As a Values-based organization, it is important for us to uphold the Values that are core to our culture and how we engage in our communities. As a global leader in public health, we want to contribute and leverage the unique insights, diversity and resources of our company to improve public health and the futures of those underserved in the communities where we live and operate.'

'We are thrilled to join forces with CSL Behring to develop a strategic plan to promote racial equity and parity while addressing critical health issues facing our communities today,' said President and CEO of the Urban League of Philadelphia Andrea Custis. 'We welcome not only CSL Behring's deep expertise and extensive resources, but also its commitment to uplifting urban and underserved communities in this time of crisis.'

CSL Behring, with global operational headquarters in the greater Philadelphia region, will initially pilot this collaboration with the Urban League of Philadelphia, focusing on leadership and career development as well as public health, with specific funding to support the Black Doctors COVID-19 Consortium.

The company will then also work directly with five other Urban League affiliates-including Chicago, Detroit, Atlanta, Baltimore and South Florida (Broward County) -- to have CSL Behring leaders volunteer on their respective boards and align on goals and priority areas of support for these regions. An additional CSL Behring contribution will go to the National Urban League Career Services Center to promote talent identification and job placement throughout the U.S.

About the Urban League of Philadelphia

The Urban League of Philadelphia, an affiliate of the National Urban League, is a nonpartisan civil rights organization that has empowered African Americans and other underserved communities for more than a century. Through housing, employment, entrepreneurship, youth development, health and wellness and advocacy, we impact more than 15,000 children, youth and families a year.

About the National Urban League

The National Urban League is a historic civil rights and urban advocacy organization with 90 affiliates serving 300 communities, providing direct services that impact and improve the lives of more than two million people nationwide.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

Contact:

Khalil Bullock

Tel: 215-406-4306

Email: Kbullock@urbanleaguephila.org

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about CSL LIMITED
01/12Australia blocks Chinese buyout of builder over security concerns -media
RE
01/11Gold miners drag down Australian shares; NZ falls 2%
RE
01/08Australia shares notch best week in 2 months on broader global rally
RE
01/07MARKET CHATTER : CSL to Finish Production of First Batch of AstraZeneca COVID-19..
MT
01/06Australian shares end 1% lower as U.S. runoff results trickle in
RE
01/05Australia shares open lower as domestic virus concerns weigh
RE
2020Australia shares dip on Sydney restrictions, NZ inches down
RE
2020Australian shares track Wall Street declines; NZ flat
RE
2020Australia shares climb as U.S. aid bill passage boosts sentiment, NZ at recor..
RE
2020Australia shares gain ahead of Christmas as virus cases plateau; NZ at record..
RE
More news
Financials (USD)
Sales 2021 10 127 M - -
Net income 2021 2 246 M - -
Net Debt 2021 4 747 M - -
P/E ratio 2021 41,8x
Yield 2021 1,06%
Capitalization 93 657 M 93 853 M -
EV / Sales 2021 9,72x
EV / Sales 2022 9,01x
Nbr of Employees 27 000
Free-Float 100,0%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 229,27 $
Last Close Price 205,85 $
Spread / Highest target 22,0%
Spread / Average Target 11,4%
Spread / Lowest Target -5,20%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Brian Anthony McNamee Chairman
Paul McKenzie Chief Operating Officer
Joy Carolyn Linton Chief Financial Officer
Andrew Cuthbertson Chief Scientific Officer & Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED-5.62%93 853
SAMSUNG BIOLOGICS CO.,LTD.-2.66%48 243
BIOGEN INC.12.65%42 447
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.-2.71%35 533
ALEXION PHARMACEUTICALS, INC.0.26%34 293
CELLTRION HEALTHCARE CO LTD--.--%19 919